Search Results - "SIGMAN, CAROLINE C."

Cancer biomarkers: selecting the right drug for the right patient by Kelloff, Gary J., Sigman, Caroline C.

“…This Perspective highlights the sources and functions as well as the evaluation of biomarkers that are useful in cancer, with a focus on those biomarkers that…”
Get full text

Considerations in the development of circulating tumor cell technology for clinical use by Parkinson, David R, Dracopoli, Nicholas, Petty, Brenda Gumbs, Compton, Carolyn, Cristofanilli, Massimo, Deisseroth, Albert, Hayes, Daniel F, Kapke, Gordon, Kumar, Prasanna, Lee, Jerry Sh, Liu, Minetta C, McCormack, Robert, Mikulski, Stanislaw, Nagahara, Larry, Pantel, Klaus, Pearson-White, Sonia, Punnoose, Elizabeth A, Roadcap, Lori T, Schade, Andrew E, Scher, Howard I, Sigman, Caroline C, Kelloff, Gary J

“…This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis,…”
Get full text

Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development by KELLOFF, Gary J, HOFFMAN, John M, SHANKAR, Lalitha, LARSON, Steven M, SIGMAN, Caroline C, SCHILSKY, Richard L, SULLIVAN, Daniel C, JOHNSON, Bruce, SCHER, Howard I, SIEGEL, Barry A, CHENG, Edward Y, CHESON, Bruce D, O'SHAUGHNESSY, Joyce, GUYTON, Kathryn Z, MANKOFF, David A

“…2-[ 18 F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect. This molecular imaging…”
Get full text

Biomarker development in the context of urologic cancers by Kelloff, Gary J., M.D, Sigman, Caroline C., Ph.D, Scher, Howard I., M.D

“…Abstract Background The Food and Drug Administration (FDA) has called for the use of analytically validated biomarkers that have strong evidence of being fit…”
Get full text

Imaging and Oncologic Drug Development by El-Deiry, Wafik S, Sigman, Caroline C, Kelloff, Gary J

“…For decades anatomic imaging with computed tomography or magnetic resonance imaging has facilitated drug development in medical oncology by providing…”
Get full text

The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development by KELLOFF, Gary J, KROHN, Kenneth A, O'SHAUGHNESSY, Joyce, CHESON, Bruce D, SIGMAN, Caroline C, TATUM, James L, MILLS, George Q, SULLIVAN, Daniel C, WOODCOCK, Janet, LARSON, Steven M, WEISSLEDER, Ralph, MANKOFF, David A, HOFFMAN, John M, LINK, Jeanne M, GUYTON, Kathryn Z, ECKELMAN, William C, SCHER, Howard I

“…As addressed by the recent Food and Drug Administration Critical Path Initiative, tools are urgently needed to increase the speed, efficiency, and…”
Get full text

The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention by KOPELOVICH, Levy, FAY, Judith R, SIGMAN, Caroline C, CROWELL, James A

“…The mammalian target of rapamycin (mTOR) is a key signaling node coordinating cell cycle progression and cell growth in response to genetic, epigenetic, and…”
Get full text

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development by PARK, John W, KERBEL, Robert S, KELLOFF, Gary J, BARRETT, J. Carl, CHABNER, Bruce A, PARKINSON, David R, PECK, Jonathan, RUDDON, Raymond W, SIGMAN, Caroline C, SLAMON, Dennis J

Get full text

Is Inducible Nitric Oxide Synthase a Target for Chemoprevention? by Crowell, James A, Steele, Vernon E, Sigman, Caroline C, Fay, Judith R

“…The molecular messenger nitric oxide (NO) is synthesized endogenously from l -arginine by three isoforms of the enzyme NO synthase. The isoform most…”
Get full text

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 by Herbst, Roy S, Gandara, David R, Hirsch, Fred R, Redman, Mary W, LeBlanc, Michael, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh S, Bradley, Jeffrey D, Sparks, Dana, Zhou, Yang, Miwa, Crystal, Miller, Vincent A, Yelensky, Roman, Li, Yali, Allen, Jeff D, Sigal, Ellen V, Wholley, David, Sigman, Caroline C, Blumenthal, Gideon M, Malik, Shakun, Kelloff, Gary J, Abrams, Jeffrey S, Blanke, Charles D, Papadimitrakopoulou, Vassiliki A

“…The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous…”
Get full text

Challenges to Using Big Data in Cancer by Sweeney, Shawn M, Hamadeh, Hisham K, Abrams, Natalie, Adam, Stacey J, Brenner, Sara, Connors, Dana E, Davis, Gerard J, Fiore, Louis, Gawel, Susan H, Grossman, Robert L, Hanlon, Sean E, Hsu, Karl, Kelloff, Gary J, Kirsch, Ilan R, Louv, Bill, McGraw, Deven, Meng, Frank, Milgram, Daniel, Miller, Robert S, Morgan, Emily, Mukundan, Lata, O'Brien, Thomas, Robbins, Paul, Rubin, Eric H, Rubinstein, Wendy S, Salmi, Liz, Schaller, Teilo, Shi, George, Sigman, Caroline C, Srivastava, Sudhir

“…Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly in oncology. These data may include electronic…”
Get full text

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications by Anderson, Kenneth C, Auclair, Daniel, Kelloff, Gary J, Sigman, Caroline C, Avet-Loiseau, Hervé, Farrell, Ann T, Gormley, Nicole J, Kumar, Shaji K, Landgren, Ola, Munshi, Nikhil C, Cavo, Michele, Davies, Faith E, Di Bacco, Alessandra, Dickey, Jennifer S, Gutman, Steven I, Higley, Howard R, Hussein, Mohamad A, Jessup, J Milburn, Kirsch, Ilan R, Little, Richard F, Loberg, Robert D, Lohr, Jens G, Mukundan, Lata, Omel, James L, Pugh, Trevor J, Reaman, Gregory H, Robbins, Michael D, Sasser, A Kate, Valente, Nancy, Zamagni, Elena

“…Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding…”
Get full text

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer by Parkinson, David R, McCormack, Robert T, Keating, Susan M, Gutman, Steven I, Hamilton, Stanley R, Mansfield, Elizabeth A, Piper, Margaret A, Deverka, Patricia, Frueh, Felix W, Jessup, J Milburn, McShane, Lisa M, Tunis, Sean R, Sigman, Caroline C, Kelloff, Gary J

“…This article defines and describes best practices for the academic and business community to generate evidence of clinical utility for cancer molecular…”
Get full text

Case Studies for Overcoming Challenges in Using Big Data in Cancer by Sweeney, Shawn M, Hamadeh, Hisham K, Abrams, Natalie, Adam, Stacey J, Brenner, Sara, Connors, Dana E, Davis, Gerard J, Fiore, Louis D, Gawel, Susan H, Grossman, Robert L, Hanlon, Sean E, Hsu, Karl, Kelloff, Gary J, Kirsch, Ilan R, Louv, Bill, McGraw, Deven, Meng, Frank, Milgram, Daniel, Miller, Robert S, Morgan, Emily, Mukundan, Lata, O'Brien, Thomas, Robbins, Paul, Rubin, Eric H, Rubinstein, Wendy S, Salmi, Liz, Schaller, Teilo H, Shi, George, Sigman, Caroline C, Srivastava, Sudhir

“…The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context…”
Get full text

A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment by Taube, Sheila E., Clark, Gary M., Dancey, Janet E., McShane, Lisa M., Sigman, Caroline C., Gutman, Steven I.

“…A workshop sponsored by the National Cancer Institute and the US Food and Drug Administration addressed past lessons learned and ongoing challenges faced in…”
Get full text

A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters by Keeney, Michael, Wood, Brent L., Hedley, Benjamin D., DiGiuseppe, Joseph A., Stetler‐Stevenson, Maryalice, Paietta, Elisabeth, Lozanski, Gerard, Seegmiller, Adam C., Greig, Bruce W., Shaver, Aaron C., Mukundan, Lata, Higley, Howard R., Sigman, Caroline C., Kelloff, Gary, Jessup, J. Milburn, Borowitz, Michael J.

“…Background Minimal residual disease (MRD) in B lymphoblastic leukemia (B‐ALL) by flow cytometry is an established prognostic factor used to adjust treatment in…”
Get full text

New science-based endpoints to accelerate oncology drug development by Kelloff, Gary J., Sigman, Caroline C.

“…Although several new oncology drugs have reached the market, more than 80% of drugs for all indications entering clinical development do not get marketing…”
Get full text

Opportunities and Challenges in Implementation of Multiparameter Single Cell Analysis Platforms for Clinical Translation by Keating, Susan M., Taylor, D. Lansing, Plant, Anne L., Litwack, E. David, Kuhn, Peter, Greenspan, Emily J., Hartshorn, Christopher M., Sigman, Caroline C., Kelloff, Gary J., Chang, David D., Friberg, Gregory, Lee, Jerry S. H., Kuida, Keisuke

“…The high‐content interrogation of single cells with platforms optimized for the multiparameter characterization of cells in liquid and solid biopsy samples can…”
Get full text

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic by Meyskens, Jr, Frank L, Curt, Gregory A, Brenner, Dean E, Gordon, Gary, Herberman, Ronald B, Finn, Olivera, Kelloff, Gary J, Khleif, Samir N, Sigman, Caroline C, Szabo, Eva

“…This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible…”
Get full text

Retinoids in chemoprevention and differentiation therapy by HANSEN, L. A, SIGMAN, C. C, ANDREOLA, F, ROSS, S. A, KELLOFF, G. J, DE LUCA, L. M

“…Retinoids are essential for the maintenance of epithelial differentiation. As such, they play a fundamental role in chemoprevention of epithelial…”
Get full text